Phase 4 N=86 Randomized Treatment

Nonopioid Pain Control Regimen After Arthroscopic Hip Procedures

Hip Arthroscopy

Bottom Line

View on ClinicalTrials.gov: NCT05076110 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Jun 2026

Primary outcome: Primary: Change in Pain Score — 4.3; 4.4; 1.8; 1.7 score on a scale

Study Design & Population

Study type: Interventional
Phase: Phase 4
Interventions: Oxycodone (Drug); Ibuprofen (Drug); Gabapentin (Drug); Acetaminophen (Drug); Methocarbamol (Drug)
Age: Pediatric, Adult, Older Adult · 16+ yrs
Sex: All
Sponsor: Mayo Clinic
Primary completion: Oct 2025

Outcome Measures

Outcome	Result	p-value
PRIMARY Change in Pain Score	4.3; 4.4; 1.8; 1.7	—
SECONDARY Change in Patient Reported Outcomes Measurement Information System (PROMIS) Pain Interference Score	61.0; 62.7; 52.3; 53.4	—
SECONDARY Change in Opioid Consumption	10.9; 0.1	—

Summary

This study is being conducted to evaluate the effectiveness of post-operative pain control without using narcotic pain medications.

Eligibility Criteria

Inclusion Criteria

Scheduled for a primary Hip Arthroscopy at Mayo Clinic (Rochester, MN)

Exclusion Criteria

medical history of known allergies or intolerance to allergies or intolerance to Motrin, Gabapentin, Tylenol, dexamethasone, tramadol, or Robaxin.
Substantial alcohol or drug abuse.
History of narcotics within 6 months of surgery.
Pregnancy.
Renal impairment.
Peptic ulcer disease.
GI bleeding.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05076110). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.